Prime Medicine, Inc. (PRME)
After hours:
Chart Events
Performance Outlook
| Previous Close | 17.58 |
| Open | 17.44 |
| Bid | 17.04 x 800 |
| Ask | 19.19 x 1200 |
| Day's Range | 16.95 - 17.79 |
| 52 Week Range | 14.52 - 21.73 |
| Volume | |
| Avg. Volume | 219,523 |
| Market Cap | 1.716B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 23.75 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for PRME
Related Research
- Prime Medicine, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic MoatyesterdayMorningstar
- Simply Wall St.
We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- GlobeNewswire
Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities
-- New preclinical data in Friedrich’s ataxia and cystic fibrosis provided further proof-of-concept for Prime Editing’s ability to achieve restoration of genetic function ---- New preliminary safety analyses demonstrated no detected off-target activity in Prime Edited Wilson’s disease cells ---- New data leveraging PASSIGE technology demonstrated ability to integrate kilobase-sized DNA in human T cells ---- Additional LNP and AAV delivery data demonstrated efficient in vivo delivery of Prime Edi
- GlobeNewswire
Prime Medicine to Present at 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. A live audio webcast of
